Apomorphine Hydrochloride Market Size, Share, Growth, And Industry Analysis, By Type (Injection, Tablets, Thin-Film, And Nasal Powder (Pipeline)), By Application (Parkinson’s Disease and Erectile Dysfunction), Regional Insights and Forecast From 2025 To 2033

Last Updated: 24 June 2025
SKU ID: 19895899

Trending Insights

Report Icon 1

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Report Icon 2

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

Report Icon 3

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels

APOMORPHINE HYDROCHLORIDE MARKET OVERVIEW

The global apomorphine hydrochloride market size was USD 0.31 billion in 2024 and is projected to touch USD 0.44 billion by 2033, exhibiting a CAGR of 3.9% during the forecast period from 2025 To 2033.

Apomorphine hydrochloride is a non-selective dopamine agonist that helps activate both D2-like and, to an extreme extent, D1-like receptors. It acts as an a-adrenergic and 5-HT2 antagonist with high affinity. It is a chemical compound that is historically a decomposition product of morphine. It is prepared by boiling morphine with concentrated acid, and thus, it has the suffix -morphine. Generally, apomorphine does not contain morphine or morphine’s skeleton; it does not bind to opioid receptors.

Apomorphine hydrochloride is used in the treatment of Parkinson’s disease and dysfunction. Parkinson’s disease is also known as a progressive neurodegenerative disorder and it affects the dopaminergic neurons in the brain. It is used to relieve pain from moderate to severe levels. The morphine extended-release capsules and tablets can only be used to cure severe uncontrollable pain by any other medications. 

COVID-19 IMPACT

Demand and Supply Chain Disturbance Hindered the Market Expansion

The sudden outbreak of the pandemic caused disruption in demand and supply chain. The manufacturing industries were shut which caused a disturbance in the manufacturing rate. The customer’s demand could not be fulfilled due to the transportation shutdown. The strict regulations and guidelines by the government did not allow any manufacturing or transportation to resume. The semiconductor and electronics industry was shut down during the pandemic, which hampered the growth of the market.

LATEST TRENDS

Rising Trials by Pharmaceuticals to Accelerate Market Growth

An increase in ongoing clinical trials being conducted by various pharmaceuticals and rising special designation from the regulatory authorities are anticipated to boost growth in the market. Moreover, the higher demand for disease-specific treatment is also expected to boost market growth. 

Apomorphine Hydrochloride Market Share, 2033

ask for customizationRequest a Free sample to learn more about this report

APOMORPHINE HYDROCHLORIDE MARKET SEGMENTATION

By Type

By type, the market is segmented–into injection, tablets, thin-film, and nasal powder (pipeline). 

By Application

Based on application, the market is classified into Parkinson’s disease and erectile dysfunction.

DRIVING FACTORS

Rising Prevalence of Disease to Increase Market Growth

The consistently rising prevalence of diseases is anticipated to bolster growth in the market. Parkinson’s disease drugs experienced increased product demand due to the rising number of patients globally. Additionally, the expanded research and support from the government and the presence of potential pipeline products are forecasted to boost the sale of Parkinson’s disease drugs. 

Use of Apomorphine Hydrochloride as a Receptor to Boost Product Demand

Apomorphine hydrochloride has various use in the treatment of various ailments. It is also used in veterinary practices and utilized as an emetic agent. It includes vomiting to manage poisoning in dogs and other animals. It helps in controlling the poison in the animals by inducing vomiting. It acts as a receptor of dopamine. 

RESTRAINING FACTORS

Risk Factors Coupled with The Intake of Medicine to Affect Market Growth

The consumption of apomorphine hydrochloride without a doctor’s prescription may affect your health and cause nausea, headache, drowsiness, yawning, pale skin, runny nose, dizziness, and hallucinations. These are the side effects of consuming the medicines or tablets that can be noticed at the beginning stage. Consuming it for a long-time may show uncontrolled movements, muscle cramps, depression, trouble sleeping, or hallucinations. These side-effects are estimated to limit the apomorphine hydrochloride market growth. 

APOMORPHINE HYDROCHLORIDE MARKET REGIONAL INSIGHTS

North America To Dominate Due To Prevalence of Chronic Diseases Among Population

North America is most likely to dominate the global market due to the rising demand for high-quality industrial valves in healthcare and pharmaceuticals. The growth of the region is also attributable to the presence of major players and the high prevalence of diseases in the general population. Additionally, the government's increasing number of research partnerships and beneficial initiatives are forecasted to be growth drivers in the market. 

Europe is also anticipated to show sizeable growth in the global market backed by the increased expenses on research and development, high incidences of Parkinson’s disease, and steady rise in the elderly population

KEY INDUSTRY PLAYERS

Key Players to Emphasize On Portfolio Development to Gain a Competitive Advantage

 Key players are anticipated to invest in research and development of the product to gain more customers in the global market. The major companies also strive to impact the market by launching new products and gaining mergers and collaborations. Companies are expected to emphasize on-demand and supply chains by offering a quick supply of the product in the market. These strategies are anticipated to gain higher growth in the apomorphine hydrochloride market and enhance the company's product portfolio. 

List of Top Apomorphine Hydrochloride Companies

  • Supernus Pharmaceuticals (U.S.)
  • Britannia Pharmaceuticals STADA (U.K.)
  • Ever Pharma (Austria)
  • Evolan Pharma AB (PharmSwed) (Sweden)
  • Tianjin Tianwei Pharmaceutical (China)
  • Sunovion (U.S.)

INDUSTRY DEVELOPMENT

  • April 2021- Optimus Pharma announced that they received the approval for their drug Safinamide from DCGI. Safinamide as an adjunctive treatment for patients suffering from Parkinson’s disease experiencing “off” episodes. The company also announced its contribution to delivering strong treatment for Parkinson’s disease in India. 

REPORT COVERAGE

The report offers a description of the product and its applications, benefits, and side effects. The market report provides insights and situations of the key players. The new strategies adopted by the key companies are covered in this report. Major key players and their headquarters are mentioned in the report to offer market insights and represent apomorphine hydrochloride market share. This report includes the factors responsible for the growth of the market and the factors expected to limit the apomorphine hydrochloride market growth.

Apomorphine Hydrochloride Market Report Scope & Segmentation

Attributes Details

Market Size Value In

US$ 0.31 Billion in 2024

Market Size Value By

US$ 0.44 Billion by 2033

Growth Rate

CAGR of 3.9% from 2024 to 2033

Forecast Period

2025-2033

Base Year

2024

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type

  • Injection
  • Tablets
  • Thinfilm
  • Nasal Powder (Pipeline)

By Application

  • Parkinson Disease
  • Erectile Dysfunction

FAQs